The role of a-synuclein in pathogenesis of familial and idiopathic forms of Parkinson's disease, and other human disorders known as a-synucleinopathies, is well established. In contrast, the involvement of two other members of the synuclein family, b-synuclein and g-synuclein, in the development and progression of neurodegeneration is poorly studied. However, there is a growing body of evidence that a-synuclein and b-synuclein have opposite neuropathophysiological effects. Unlike a-synuclein, overexpressed b-synuclein does not cause pathological changes in the nervous system of transgenic mice and even ameliorates the pathology caused by overexpressed a-synuclein. To assess the consequences of excess expression of the third family member, g-synuclein, on the nervous system we generated transgenic mice expressing high levels of mouse g-synuclein under control of Thy-1 promoter. These animals develop severe age-and transgene dose-dependent neuropathology, motor deficits and die prematurely. Histopathological changes include aggregation of g-synuclein, accumulation of various inclusions in neuronal cell bodies and processes, and astrogliosis. These changes are seen throughout the nervous system but are most prominent in the spinal cord where they lead to loss of spinal motor neurons. Our data suggest that down-regulation of small heat shock protein HSPB1 and disintegration of neurofilament network play a role in motor neurons dysfunction and death. These findings demonstrate that g-synuclein can be involved in neuropathophysiological changes and the death of susceptible neurons suggesting the necessity of further investigations of the potential role of this synuclein in disease.
INTRODUCTION
The importance of a-synuclein in the development and progression of the human disorders known as synucleinopathies is beyond doubt although the exact mechanism of neurodegeneration induced by dysfunction of this protein is the subject of heated debate [for recent reviews see Ref. (1)]. On the other hand, b-synuclein is believed to be a neuroprotective factor-in several experimental in vivo systems, expression of this protein ameliorated neuronal pathology caused by overexpression of a-synuclein (2 -7).
Despite limited information, certain known properties of g-synuclein place it structurally and functionally in between the other two members of the synuclein family. For instance, g-synuclein adopts a free-state residual secondary structure similar to a-synuclein whereas in an extended mode its structure resembles b-synuclein (8) . These structural differences correlate with different propensities of the synucleins to aggregate. Aggregation of a-synuclein in vivo is believed to be a crucial event in pathogenesis of these diseases, with intermediates (i.e. soluble oligomers) and final products (i.e. larger, insoluble and immunohistochemically detectable aggregates) playing different but equally important roles (1, 9, 10) . Conversely, a protective function of b-synuclein seems to correlate with its negligible propensity to aggregate and its ability to retard the aggregation of a-synuclein in vitro (2,11 -13) . g-Synuclein is able, albeit less efficiently than a-synuclein, to aggregate and form fibrils in vitro. However, like b-synuclein, it has also been shown to inhibit the aggregation of a-synuclein (11, 12) . In contrast to a-synuclein, acute overexpression of g-synuclein does not induce death of cultured neurons but perturbs their neurofilament network by an unknown mechanism (14, 15) .
While a-synuclein is the major component of Lewy bodies and other histopathological hallmarks of synucleinopathies, neither b-synuclein nor g-synuclein have been found in these structures. Nonetheless, changes in their expression or distribution (16 -18) and accumulation of these proteins in unconventional histopathological lesions within neurons and axons (Refs 19-21 and our unpublished observations) have been observed in several human neurodegenerative disorders as well as certain transgenic or pharmacological animal models of neurodegeneration (16,22 -26) . Therefore, it is tempting to speculate that accumulation and aggregation of g-synuclein might be a causative factor in the development of certain, yet to be identified, types of neurological disorders.
To test whether increased and/or ectopic expression of mouse g-synuclein could trigger neurohistopathological changes and phenotypes typical for synucleinopathies, we produced transgenic mice with pan-neuronal overexpression of this protein. Animals expressing high levels of g-synuclein develop severe and fatal neurological disease associated with aggregation of the overexpressed protein and its deposition in cytoplasmic and axonal lesions.
RESULTS

Production of transgenic animals and analysis of transgene expression
Transgenic mice expressing elevated levels of mouse wildtype g-synuclein were generated using the Thy-1 neuronspecific expression cassette (Fig. 1A ) that we and others have used previously for generating lines expressing high levels of either a-synuclein (27 -30) or b-synuclein (5). Mice from one line, Thy1mgSN, expressed high levels of mouse g-synuclein throughout the nervous system and developed an age-dependent neurological phenotype. Mice of a second line with lower levels of the transgene expression did not develop a noticeable phenotype and were excluded from this study.
Transgenic mice were produced on a pure genetic background and the colony was maintained by backcrossing hemizygous Thy1mgSN mice with C57Bl6 mice. These hemizygous animals were indistinguishable from their wildtype littermates during the first year of their life. Later most of these mice developed a clasping reflex, abnormal posture and gait, as well as other signs of motor dysfunction (see below). In an attempt to augment the pathology we bred Thy1mgSN mice to homozygosity. This resulted in an approximate doubling of the transgene expression levels, which in dorsal root ganglia (DRG) of 12-month-old mice reached the level that was approximately seven times higher than the level of endogenous g-synuclein mRNA in these ganglia (Fig. 1B) . Offspring from intercrosses of hemizygous parents showed a normal Mendelian distribution of genotypes. Homozygous animals appeared normal during the first few months of life despite a very high level of g-synuclein mRNA expression throughout their nervous system. For instance, in the spinal cord of young adult homozygous transgenic animals, the level of this mRNA was approximately 16 times higher than in the trigeminal ganglion of wild-type mice that was used for reference due to the high endogenous level of g-synuclein mRNA expression and homogeneity of cell population in this structure (Fig. 1B, top panel) . In the spinal cord of wild-type animals, only motor neurons express g-synuclein (31), but in Thy1mgSN mice, motorneurons and additional types of spinal neurons expressed g-synuclein, which explains, in part, the robust increase of both g-synuclein mRNA (Fig. 1B, bottom panel) and protein ( Fig. 1C and D) levels. The same applied to other regions ( Fig. 1D and data not shown) where endogeneous g-synuclein expression is restricted to certain neuronal populations (32) but the transgene is expressed in the majority of neurons. Substantial accumulation of g-synuclein did not affect the levels of expression of the other two members of synuclein family (Fig. 1D) .
Overexpression of g-synuclein is associated with a severe neurological phenotype and early lethality of transgenic mice
The health of homozygous animals started to deteriorate substantially from the age of 6 -9 months. The first signs of pathology were similar to those observed in the older hemizygous mice, including clasping reflex, hunchback posture and abnormal gait ( Fig. 2A-C and Supplementary Material movie). In contrast to hemizygous animals, clinical signs of pathology in homozygous animals progressed rapidly with all animals developing pareses of their limbs by the age of 9 -16 months followed by paralyses and loss of the righting reflex (Fig. 2D) . At this stage, the animals were sacrificed to prevent further suffering. Typically, the paraparesis of the forelimbs became obvious earlier than that of the hindlimbs. Lifespan of homozygous transgenic mice was also limited; not a single mouse survived beyond the age of 16 months in two independent cohorts (total 74 mice) housed in two animal facilities (Fig. 2E) .
The onset and progression of motor dysfunction was quantified using several different tests. Balance and coordination were already significantly impeded in homozygous Thy1mgSN mice younger than 6 months before they displayed obvious clinical signs of pathology (Fig. 3 and Supplementary  Material Tables S1 and S2) . Their ability to turn on an 11 mm diameter beam and their performance on a constant speed rotarod were both compromised by the age of 4 months ( Fig. 3A and Supplementary Material Table S1 ). Using the accelerating rotarod test, it was possible to demonstrate motor impairments as early as at 2 months of age. At this time point the homozygous Thy1mgSN mice were indistinguishable from wild-type mice by any other criteria examined (Fig. 3B) . Hemizygous Thy1mgSN mice developed a similar motor dysfunction but with a much greater latency and slower progression. This is exemplified by their performance on the rotarod that only declined significantly after the age of 18 months (Fig. 3) . In the footprint test, the length of stride of hemizygous 18-month-old animals was significantly shorter than that of their wild-type littermates, while homozygous mice already showed this impairment at the age of 6 months (Supplementary Material Fig. S1 and data not shown). The horizontal beam test was most sensitive for detecting early signs of motor deficit in hemizigous Thy1mgSN animals; their ability to perform both parts of the task was already obviously compromised at the age of 12 months (Supplementary Material Tables 1 and 2 ).
In summary, pan-neuronal overexpression of mouse g-synuclein in transgenic mice was associated with a progressive age-and gene dose-dependent motor phenotype that recapitulates phenotypes described earlier for several lines expressing human a-synuclein under control of the same Thy-1 promoter or other pan-neuronal promoters (27, 30, (33) (34) (35) (36) (37) (38) (39) .
Aggregation and fibrillation of g-synuclein in the nervous system of transgenic mice It was feasible to suggest that pathological changes in the nervous system of Thy1mgSN transgenic mice would also be similar to the changes observed in the nervous system of a-synuclein transgenic animals and might be accompanied by aggregation of g-synuclein in neurons and their processes. Therefore, we looked for signs of g-synuclein aggregation throughout the nervous system of homozygous Thy1mgSN mice that developed obvious pathology.
Immunohistochemical analysis of Thy1mgSN brain and spinal cord sections stained with highly specific SK23 antibody (31) revealed increased production of g-synuclein in many neurons expressing endogenous g-synuclein as well as ectopic production in other neurons normally devoid of this protein. In contrast to the predominantly neuritic localization of endogenous g-synuclein in the brain of adult wild-type mice (32) , overproduced protein also accumulated in the neuronal cell bodies (Supplementary Material Fig. S2 ). Although immunostaining in the majority of transgenic mouse brain neurons was diffusely distributed throughout the cytoplasm, in subsets of neurons, we detected g-synuclein-positive cytoplasmic inclusions which, in some cases, were clearly eosinophilic and also showed some remarkable resemblance to the a-synuclein-positive structures seen in Lewy body diseases ( Fig. 4A and Supplementary Material Fig. S2D and E). However, much more typical was the presence of g-synuclein-positive spheroids and dystrophic neurites ( Fig. 4A and Supplementary Material Fig. 2D and E) that were not seen in the nervous system of wild-type littermates ( Fig. 4A and data not shown).
These abnormal structures were observed throughout the nervous system but were most abundant in the spinal cord ( Fig. 4A) , which is consistent with the observed clinical pattern of pathology. Therefore, the spinal cord was used to determine whether aggregated and fibrillated forms of g-synuclein were present in neuronal tissues of animals overexpressing this protein. Sequential fractionation of the spinal cord tissues demonstrated that, in contrast to endogenous Figure 3 . Rotarod performance of g-synuclein transgenic mice. Groups of mice of different ages and genotypes were tested on Ugo Basile rotarod using constant speed (A) or accelerating (B) modes as described in Material and methods. Line graphs show mean + SEM of latency to fall for wild-type (diamonds), hemizygous Thy1mgSN (squares) and homozygous (triangles) Thy1mgSN mice at different age. Statistically significant difference (P , 0.01, Student's t-test) in performance between transgenic and wild type groups at particular age is denoted by asterisks.
g-synuclein, which was completely soluble in salt/non-ionic detergent buffers, a substantial fraction of g-synuclein in the spinal cord of Thy1mgSN mice remained insoluble after extraction with these solutions but could be partially solubilized in the ionic detergent-containing buffers (Fig. 4B ) or in formic acid (data not shown). Immuno-electron microscopy of sarcosyl-insoluble material revealed the presence of filaments decorated with antibody against g-synuclein (Fig. 4C ). These results demonstrate that increased expression of g-synuclein in mouse neurons can cause aggregation and fibrillation of this protein followed by formation of large intracellular inclusions.
Histopathology in the spinal cord of transgenic mice
Amyloid-like inclusions were detected by Congo Red ( Neuronal degeneration is commonly associated with the activation of microglia and astroglia in affected regions of the nervous system. A large number of GFAP-positive cells with morphology typical for activated astrocytes were found in the spinal cord gray matter of severely affected homozygous Thy1mgSN mice (Fig. 6A ). The level of GFAP was also substantially increased in the spinal cord tissue of homozygous and, to a lesser extent, age-matched hemizygous animals without obvious signs of pathology ( Fig. 6B) but not in the spinal cord of young homozygous mice. However, using antibodies against two different markers, Iba1 and CD11b, we failed to detect clear signs of microglia activation (data not shown).
Another common feature of synucleinopathies is the presence of ubiquitin-positive inclusions in affected regions of the nervous system. In the spinal cord of g-synuclein transgenic animals, we detected multiple abnormal ubiquitinpositive structures (Fig. 6C) . However, double immunofluorescence revealed only partial overlap between g-synucleinpositive and ubiquitin-positive profiles (Fig. 6D) . Furthermore, western blot analysis did not reveal g-synuclein-laddered staining patterns reminiscent of different degrees of ubiquitination (for example, see Fig. 1D ). Therefore, most of the aggregated g-synuclein in the spinal cord of Thy1mgSN mice are probably not ubiquitinated, but ubiquitin and/or some ubiquitinated proteins are present in the inclusions that appear in the nervous system of these mice.
Loss of motor neurons in the spinal cord of transgenic mice
The emergence of pathological inclusions and astrogliosis in Thy1mgSN mice coincides with the loss of motor neurons in the spinal cord (Fig. 7) . Twelve-month-old homozygous animals with severe motor impairments possessed less than 40% of their wild-type littermates spinal motor neuron complement (Fig. 7E ). Age-matched hemizygous and homozygous mice that developed milder motor impairment (clasping reflex and pareses of one limb but normal righting, for example see Supplementary Material movie) also displayed motor neuron loss but to a far lesser extent (Fig. 7E) . Similar results were obtained in cervical, thoracic and lumbar parts of the spinal cord (data not shown). Neurodegeneration in the spinal cord of motor neuron disease patients is often associated with dysfunction of intracellular systems that are responsible for correct folding of protein molecules. Survival of spinal motor neurons seems to rely on molecular chaperons including small heat shock proteins (40 -44) . Therefore, we used western blot analysis to examine the levels of large (HSP70) and small (HSPB1 also known as HSP27 or, in mouse, HSP25) heat shock proteins in the spinal cords of Thy1mgSN mice. While the levels of HSP70 were similar in age-matched transgenic and wild-type animals, the levels of HSPB1 were dramatically increased in all ageing transgenic animals and particularly in those that displayed severe motor impairment (Supplementary Material Fig. S3 ). However, this increase was due to high levels of HSPB1 in activated astrocytes ( Fig. 7F and Supplementary Material Fig. S4 ), whereas in spinal motor neurons of transgenic animals the level of this protein was substantially lower than in spinal motor neurons of wildtype mice (Fig. 7F) . Neurofilaments in the spinal cord and peripheral nerves of transgenic mice HSPB1 is thought to be involved in regulation of the neurofilament network assembly in normal motor neurons and its mutant variants affect neurofilament-L (NF-L) aggregation in certain forms of Charcot -Marie -Tooth disease (45 -47) . An acute overexpression of g-synuclein in cultured neurons also perturbs their neurofilament network integrity (15) . Therefore, we analysed neurofilaments in the spinal motor neurons of transgenic mice chronically overexpressing g-synuclein. Western blot analysis of the non-ionic detergent soluble fraction of Thy1mgSN mouse spinal cord revealed not only monomeric full-length 67 kDa NF-L but also distinct lower molecular weight NF-L species (Fig. 8A) , possibly products of specific and restricted breakdown that were not seen in similar fractions of wild-type mouse spinal cord tissue. Decrease of these truncated species in the spinal cord of severely affected animals probably reflects loss of neurons that produced them. Overexpressed g-synuclein co-immunoprecipitated with soluble NF-L, although substantially less amount of this protein was pulled-down from spinal cord lysates of animals at the advance stages of pathology than from similar lysates of less-affected animals (Fig. 8B) .
Immunostaining of histological sections with antibody against NF-L did not reveal accumulation of this protein in g-synuclein-positive or any other pathological profiles in the spinal cord of transgenic animals (Fig. 8C) . However, substantial reduction in staining intensity in the spinal cord of Thy1mgSN mice when compared with wild-type tissue was observed (Fig. 8C) . This reduction was mainly confined to neuronal processes and not the motor neuron cell bodies (Fig. 8D, upper panels) . It was even more obvious in longitudinal sections through peripheral nerves of Thy1mgSN mice where only thin and wavy neurofilament-positive strings were found (Fig. 8D, lower panels) . In addition, severe axonal pathology in the form of multiple nerve fibre swellings was revealed in the sciatic nerve of ageing homozygous Thy1mgSN mice (Fig. 8D, lower panels) . Similar changes were also observed in tissue sections stained with antibodies against two other neurofilament proteins (data not shown). These results suggest that overexpression of g-synuclein in transgenic mouse neurons seriously compromises the organization of neurofilaments in neuronal processes and, consequently, the architecture and function of axons.
DISCUSSION
Previous studies of transgenic mice overexpressing members of the synuclein family have revealed the contrasting effects of a-synuclein and b-synuclein on the development of pathological changes in the nervous system of these animals. High levels of a-synuclein in neurons cause a prominent neurological phenotype although the manifestations are variable and dependent on the a-synuclein isoform and type of promoter used for production of that particular transgenic line (reviewed in Refs. [48] [49] [50] . In contrast, overexpression of b-synuclein does not have a harmful effect on animal health and even counteracts a-synuclein neurotoxicity (5 -7). These results echo differences in aggregation propensity, cytotoxicity and certain structural features of these two proteins. As discussed in the Introduction, g-synuclein has molecular features shared with both a-and b-synuclein. Therefore, it was not possible to predict the consequences of g-synuclein overexpression in the nervous system of transgenic animals. Revealing the effects of aberrant expression of g-synuclein in vivo is important not only for better understanding of relationships between structure and function within synuclein family. This information would also be valuable for development of new therapeutic approaches to combat synucleinopathies.
No disease-associated mutations of g-synuclein gene or obvious cases of idiopathic human g-synucleinopathies have been reported so far and the amino acid similarity between human and mouse proteins is high. Taking these facts into consideration, we decided to create a simple homologous model in which mouse g-synuclein was overexpressed in the majority of neurons of the mouse nervous system. To achieve this we produced Thy1mgSN transgenic mice, expressing high levels of mouse g-synuclein under control of the Thy-1 promoter cassette that has previously been used for producing several a-synuclein (27 -30) and a b-synuclein (5) transgenic animal lines. In relatively homogeneous populations of neurons that normally express g-synuclein, for example the DRG, there was approximately a 7-fold increase of g-synuclein mRNA expression in homozygous Thy1mgSN transgenic mice compared with wild-type mice.
In homozygous transgenic mice, g-synuclein aggregates and accumulates in abnormal structures within neuronal cell bodies and neurites. These g-synuclein-positive structures resemble pathological hallmarks of synucleinopathies, namely dystrophic, beaded and ballooned neurites, spheroids, and even, occasionally, Lewy bodies. Like aggregated a-synuclein, aggregated g-synuclein could not be extracted from transgenic mouse neural tissues using non-ionic detergents, but is partially soluble in sarcosyl-containing buffers. At least a fraction of aggregated g-synuclein forms linear fibrils that are structurally similar, although not identical to products of a-synuclein fibrillation in vivo or in vitro.
Multimeric forms of a-synuclein are commonly detected on western blots of SDS-soluble proteins extracted from neural tissues of patients suffered from synucleinopathies or a-synuclein transgenic mice (35,37,38,51 -55) . These higher molecular weight bands represent either SDS-resistant a-synuclein oligomers or ubiquinated forms of the protein.
We did not observe similar concatomeric g-synuclein species in extracts of g-synuclein transgenic mouse brain or spinal cord. This might suggest that the oligomeric intermediates of g-synuclein aggregates are either not accumulating to a significant level in neurons of transgenic mice or that they are readily solubilized to monomeric g-synuclein in SDS-containing buffers. It also suggests that even aggregated g-synuclein is rarely ubiquitinated, which is consistent with our observation that g-synuclein-positive inclusions in the spinal cord of transgenic mice often do not co-localize with ubiquitin-positive structures. The most probable explanation of our results is that ubiqutination is neither required for nor accompanies g-synuclein aggregation but ubiquitin or certain ubiquitinated proteins may accumulate in pathological inclusions. Moreover, pathological changes in the nervous system of transgenic mice may trigger secondary events, including aggregation of ubiquitinated proteins and formation of ubiquitin-positive/g-synuclein-negative inclusions that we have observed on double-immunostained sections of the spinal cord. Similar partial overlap of a-synuclein and ubiquitin staining patterns has been found previously in the nervous systems of patients with synucleinopathies and a-synuclein transgenic mice, though ubiquinated a-synuclein is relatively abundant in these tissues (56) .
The common features of a-synuclein pathology in human patients and transgenic mice are abundant amyloid deposits and activated glial cells in affected areas of the nervous system. In the brain and spinal cord of g-synuclein transgenic mice, we also observed multiple amyloid (Congo Red-and Thioflavin S-positive) deposits and prominent astrogliosis, but no activated microglia was detected.
Although all pathological changes described above were observed throughout the central nervous system of Thy1mgSN mice, the spinal cord was noticeably more affected than any other region, which is similar to the reports on transgenic mice expressing a-synuclein under control of the same Thy-1 promoter (Refs 27,29,57 and our unpublished observations). This probably reflects the higher sensitivity of spinal cord neurons, particularly motor neurons, to high levels of both members of the synuclein family.
The ultimate consequence of g-synuclein overexpression in transgenic mice is death of motor neurons. Correspondingly, these mice display clinical signs typical for motor neuron disease, namely a gradual development of motor deficit followed by pareses and paralyses, which are most obvious in limb muscles. At this terminal stage of the disease, g-synuclein transgenic animals lose more than 60% of ventral horn motor neurons.
The development of neurological phenotype and histopathological findings in our mice suggests that pan-neuronal overexpression of g-synuclein in mice could trigger pathological changes typical for synucleinopathies and most apparent in the spinal cord. The burden of pathology increases with age, which leads to a gradual loss of spinal motor neurons and the development of motor dysfunction. The onset, penetrance and degree of neuropathology directly correlate with the level of transgene expression because the hemizygous animals, which express 50% less transgenic g-synuclein than the homozygous animals, develop clinical signs later in their life and show less pronounced histopathological changes in their nervous system. One intriguing question is which molecular and cellular processes previously linked to the development of neurodegeneration become compromised in the nervous system of g-synuclein transgenic mice? Recent studies on the mechanisms of neurodegeneration in humans and in various model organisms demonstrate that simultaneous dysfunction of several systems safeguarding cell homeostasis is required for the development of a full-scale pathology. However, some types of neurons are particularly sensitive to dysfunction in certain intracellular systems. Pathogenesis of motor neuron diseases often involves disruption of neurofilament networks in motor neuron cell bodies and axons (reviewed in Refs 58-61). While this disruption could be triggered by various mechanisms, in the majority of cases changes in the structure or metabolism of NF-L, a subunit required for assembly of neurofilaments in vivo, play a crucial role (45, (62) (63) (64) (65) (66) (67) . We have demonstrated that chronic overexpression of g-synuclein in mouse motor neurons leads to substantial depletion of neurofilaments in neuronal processes. This might be an essential event in pathogenesis of axonal pathology in peripheral nerves and consequent development of motor dysfunction in g-synuclein transgenic mice. This result is consistent with our previous findings that acute overexpression of g-synuclein affects neurofilament network integrity in cultured neurons, particularly their axons (15) . The exact mechanism of the disruptive effect of overexpressed g-synuclein on neurofilaments remains to be elucidated but its ability to interact with soluble NF-L and accumulation of abnormal NF-L-reactive soluble polypeptides in the spinal cord of Thy1mgSN mice suggest that normal homeostasis, including transport of NF-L to axons, might be at least partially prevented by trapping this protein in complexes with g-synuclein and/or abnormal degradation. Disruption of axonal neurofilaments follows the reduction of NF-L axonal traffic. Moreover, truncated NF-L species could also affect neurofilament assembly and/or stability.
Some histopathological changes observed in Thy1mgSN mice, including astrocytosis and loss of motor neurons and their axons, are similar to those observed in aged NF-L null mutant mice (67) . However in g-synuclein transgenic mice, the pathological phenotype develops much earlier and is substantially more severe. This suggests that, in addition to the disrupted neurofilament network, other intracellular systems are also compromised in the motor neurons of these animals. Molecular chaperons belonging to the family of heat shock proteins play an important protective role in motor neurons. These cells seem to be particularly vulnerable to dysfunction of the small heat shock protein HSPB1 (40 -44) and mutations of the HSPB1 gene cause certain types of motor neuron diseases (45 -47) . In motor neurons of g-synuclein transgenic mice, the level of HSP25, a mouse ortholog of HSPB1, is substantially reduced, potentially compromising the survival of these cells.
Although some a-synuclein transgenic mice develop similar clinical signs of the spinal cord pathology to g-synuclein transgenic mice, neither down-regulation of HSPB1 nor changes of the neurofilament network in their motor neurons has been reported. Taken together with other data, this suggests that diverse but partially overlapping mechanisms underlie development of pathology in these two mouse models. In conclusion, we have demonstrated that transgenic mice expressing high levels of g-synuclein in their neurons develop a severe neurodegenerative pathology. It is feasible that, under certain conditions, g-synuclein could be involved in the development of pathological changes in human neurons. Further studies on the role of this synuclein in normal and degenerating neurons might therefore provide additional insight into the mechanisms leading to human neurodegenerative diseases.
MATERIALS AND METHODS
Generation of transgenic animals
A fragment of mouse g-synuclein cDNA including 34 bp of 5 0 -UTR and 64 bp of 3 0 -UTR was PCR amplified using pD53 plasmid DNA (31) as a template and oligonucleotides with XhoI linkers (mgSN XhoI-F: 5 0 -CTACTGTCCGCTCG AGCTTGCAGCAGCCAGGTTC-3 0 and mgSN XhoI-R: 5 0 -CTACTGTCCGCTCGAGGCCTTCTAGTCTTCTCCA-C-3 0 ) to facilitate subsequent cloning into XhoI site of Thy-1 promoter plasmid 323-pTSC21k (27) . The fragment for microinjecting mouse oocytes was isolated by digestion of the resulting plasmid DNA with NotI. Transgenic founders were produced on C57Bl6 genetic background. Animals positive for transgene expression were crossed with C57Bl6 wild-type mice. Transgenic and wild-type animals were identified by PCR analysis of DNA from ear biopsies. The presence of a 1 kb product in the amplification reaction with primers HP45 ThyI f2 (5 0 -ACACCCCTAAAGCATACAGTCAGAC C-3 0 ) and HP84 m gSN (5 0 -GGCCTTCTAGTCTTCTCCA CTCTTG-3 0 ) indicated the presence of transgene in the mouse genome. Experimental cohorts were formed from litters produced by intercrossing hemizygous animals. Hemiand homozygous animals were discriminated by quantitative real-time PCR analysis of DNA from ear biopsies and verified by analytical backcrossing followed by offspring genotyping. All animal work was carried in accordance with the United Kingdom Animals (Scientific Procedures) Act (1986).
Motor performance tests
Rotarod tests. Animals were tested on Ugo Basile 7650 rotarod at 2, 4, 6, 9, 12, 18 and 24 months of age. A constant (24 rpm) speed test was carried out for 4 min and accelerating (4-40 rpm) speed test for 5 min as described previously (68) . Each mouse was tested three times in each mode with at least 30 min rest between trials. The mean of latency to fall for these three trials was included in final statistics. Horizontal beam test. Animal coordination was tested on an 11 mm diameter and 50 cm long horizontal wooden rod at 4, 6, 9 and 12 months of age. A mouse was placed at the free hanging end of the rod facing its end. The ability to turn 1808 and to reach an escape black box at the other end of the rod was recorded.
Footprint test. Animals were trained to run along a narrow passage lined with a strip of white paper before carrying out the test run. For this run, mouse forefeet were coated with blue ink and hindfeet with red ink. Different parameters of the stride were measured and analysed as described previously (69) .
RNA expression analysis
Total RNA from various regions of the nervous system was extracted using RNAEasyþ kit as recommended by the manufacturer (Qiagen). First-strand cDNA was synthesized using random primers (Promega) and SuperScriptIII reverse transcriptase (Invitrogen). Quantitative PCR was performed on StepOne Real-Time PCR System (Applied Biosystems) with DyNAmo HS SYBR Green supermix (Finnzymes) and ROX as a passive reference dye. Reactions were carried out in onepiece thin-wall 48-well PCR plates (Bioplastics). GAPDH mRNA was used as a normalization standard. Primers 5 0 -CCATGGACGTCTTCAAGAAAGG-3 0 and 5 0 -CGTTCTC CTTGGTTTTGGTG-3 0 were used for amplification of g-synuclein cDNA, and primers 5 0 -CACTGAGCATCTCC CTCACA-3 0 and 5 0 -GTGGGTGCAGCGAACTTTAT-3 0 for amplification of GAPDH mRNA. After hot start (10 min at 958C), 40 cycles of 15 s at 958C and 60 s at 608C were carried out followed by melting curve determination with 0.38C steps. Fold change was determined by 2 2DDCT method as described previously (70) using StepOne v2.0 software.
Protein extraction
Total tissue proteins were extracted by homogenization of tissues directly in SDS-PAGE loading buffer followed by incubation for 10 min at 1008C. For analysis of cytosolic proteins, tissues were homogenized in 50 mM Tris -HCl, pH 7.5; 150 mM NaCl; 1% Triton X-100 buffer with protease inhibitors (Complete Mini from Roche) and cytosolic fraction was obtained by centrifugation for 10 min at 10 000g.
Sequential protein extraction
A previously described protocol (37) was used with minor modifications. Briefly, neuronal tissues were homogenized in 5 volumes of high salt (HS) buffer (50 mM Tris -HCl, pH 7.5; 750 mM NaCl; 5 mM EDTA) with protease inhibitors (Complete Mini from Roche) and centrifuged at 100 000g for 20 min at 48C. Pellets were washed in the same buffer and then re-extracted in HS buffer containing 1% Triton X-100 (HS/T-soluble fraction). Subsequent centrifugations and re-extractions produced RIPA-soluble and SDS-soluble fractions. The presence of g-synuclein in these fractions was analysed by SDS -PAGE/western blotting.
Isolation and visualization of g-synuclein filaments
Sarcosyl-insoluble filaments were extracted from mouse spinal cords as described previously for human neuronal tissues (71) .
Final 100 000g pellets were resuspended in 50 mM Tris-HCl (pH 7.5) buffer and aliquots were applied onto glowdischarged carbon-coated 400-mesh copper grids. After blocking in 1% BSA/PBS, grids were incubated in 1:50 diluted affinity purified rabbit anti-mouse g-synuclein SK23 antibody (31) for 60 min at room temperature followed by goat antirabbit immunoglobulin secondary antibody (Amersham) conjugated to 10 nm gold particles. Fibrils were negatively stained with 1% dodeca-tungstophosphoric acid neutralized with KOH to pH 6.2 as described previously (72) and observed at Â40 000 or Â50 000 magnification under a Philips TEM 208 transmission electron microscope.
Western blotting and antibodies
Proteins separated by SDS -PAGE were transferred to PVDF membrane using iBlot technology according to manufacturer (Invitrogen) instructions. Membrane blocking, incubation with antibodies, washing and chemiluminescent detection using ECL or ECL þ techniques were carried out as described previously (31, 68) . Intensities of bands obtained using AlphaImager 2200 were analysed using AlphaEase 2200 Analysis Software (AlphaInnotech Corporation). Primary antibodies against GAPDH (mouse monoclonal, clone 6C5, Santa Cruz Biotechnology), a-synuclein (mouse monoclonal, clone 42, BD Transduction Laboratories), b-synuclein (mouse monoclonal, clone 8, BD Transduction Laboratories), g-synuclein (rabbit polyclonal SK23, affinity purified), GFAP (rabbit polyclonal, Sigma), Iba1 (mouse monoclonal, clone 1022-5, Santa Cruz), CD11b (rat monoclonal, clone M1/70.15, Serotec), NF-L (rabbit monoclonal, clone C28E10, and mouse monoclonal, clone DA2, both Cell Signalling), neurofilament H (rabbit polyclonal, Sigma), heat shock protein B1 (rabbit monoclonal, Cell Signalling) and heat shock protein 70 (rabbit monoclonal, Cell Signalling) were used.
Immunoprecipitation
Freshly dissected spinal cords from individual animals were homogenized in 0.5 ml of IP buffer (50 mM Tris -HCl, pH 7.5, 300 mM NaCl, 1.5 mM MgCl 2 , 1% Triton X-100) with protease inhibitors (Complete Mini from Roche) and Tritonsoluble fraction was obtained by Â10 000g centrifugation for 10 min at 48C. After presorption on Protein G Sepharose (Amersham) for 30 min at 48C and removal of beads by centrifugation for 1 min at 1000g, 5 ml of antibody against NF-L (mouse monoclonal, clone DA2, Cell Signalling) or 20 ml of antibody against g-synuclein (rabbit polyclonal SK23) were added, followed by 50 ml of fresh Protein G Sepharose. The suspension was rotated at 48C for 2 h Sepharose beads were collected by centrifugation for 1 min at 1000g and washed four times with IP buffer. Bound proteins were eluted by boiling beads in 50 ml of SDS -PAGE loading buffer for 10 min.
Histological techniques
Dissected tissues were post-fixed in 4% paraformaldehyde/ PBS or Carnoy's fixative and embedded in paraffin wax. Eight micrometre thick sections were cut and immunostained as described previously (32) using Elite plus kits (Vector laboratories) and 3,3 0 -diaminobenzidine as a substrate. For double immunofluorescence, secondary Alexa Fluor-conjugated antibody (Invitrogen) were used. Images were prepared using laser scanning confocal microscope Leica TCS SP2 (Leica Microsystems) and LEICA CONFOCAL 2.00 software. For detection and counting of amyloid aggregates, spinal cord sections (four to five animals per age/genotype/condition group) were stained in 0.5% Congo red solution in 50% ethanol for 7 min followed by a brief differentiation in potassium hydroxide (0.2% in 80% ethanol) and, after several washes in dH 2 O, were mounted using Immu-mount (Thermo Electron Corporation). Fluorescent microscopy was used to analyse the number of aggregates within a randomly selected 0.1 mm 2 area of the spinal cord gray matter. For assessing number of spinal motor neurons, transverse spinal cord sections were stained in 0.5% cresyl fast violet (CFV) solution in dH 2 O and dissociated in acidified ethanol (0.25% acetic acid in ethanol). The number of motor neurons (identified by a large cell body containing Nissl granules, with a clear nuclear envelope containing a strongly stained nucleolus) within the ventral horn was counted. Results were expressed as per cent of the average number of motor neurons per ventral horn section in the wild-type animals.
